Salmon calcitonin

Composition

Salcatonin is composed of 32 amino acids, of which 13 differ from human calcitonin. The structure of human calcitonin and salcatonin is as follows:

Human calcitonin:

H-Cys1-Gly-Asn-Leu-Ser-Thr-Cys7-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-lle-Gly-Val-Gly-Ala-Pro-NH2

Salcatonin:

H-Cys1-Ser-Asn-Leu-Ser-Thr-Cys7-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2

The cysteine in the first and seventh positions form a disulfide bond.

Therapeutic usage

Synthetic salmon calcitonin may be used therapeutically in humans, as it is twenty times more active than human calcitonin and has a longer half-life. It is used as therapy for Paget's disease, severe hypercalcemia, and in some cases, gynecomastia. It is also used as a therapy against osteoporosis working as an inhibitor of osteoclastic resorption and production of osteoclast precursors), having an effectiveness of 40-50 times that of the human analogue. They may also have analgesic effects, relieving bone pain.

Pharmaceutical salmon calcitonin formulations

Calcitonin, as salmon calcitonin (sCT), is available in the pharmaceutical market as an injectable preparation for intravenous, intramuscular or subcutaneous application. Noninvasive sCT preparation as a nasal spray is commercially produced and received US FDA approval under the proprietary name Miacalcin® in 1975 for the treatment of postmenopausal osteoporosis. The bioavailability of Miacalcin® nasal spray relative to the injectable form is between 3% and 5%. Currently, a number of sCT oral preparations are under clinical trials and at least one of them has reached Phase III of clinical approval.

References

References

1. (1 May 2020). "Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice". Neuropharmacology.
2. (1996). "Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.". Drugs & Aging.
3. (2016). "Reference Module in Biomedical Sciences". Elsevier.
4. (1994-08-13). "Salcatonin and gynaecomastia". The Lancet.
5. (September 5, 1992). "Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study". British Medical Journal.
6. (2008). "Salmon calcitonin: a review of current and future therapeutic indications". Osteoporos Int.
7. (2014). "Mucosal Delivery of Biopharmaceuticals". Springer US.